
Sign up to save your podcasts
Or


In this week’s View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss a prespecified analysis of the DELIVER Trial that investigated the efficacy and safety of dapagliflozin according to frailty in patients with heart failure, then looks at a separate paper on the DELIVER Trial that examines dapagliflozin for heart failure according to body mass index. Finally, Dr. Bhatt examines a prospective cohort study of UK Biobank participants that looked at the association between device-measured physical activity and incident heart failure.
By American College of Cardiology4.7
129129 ratings
In this week’s View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss a prespecified analysis of the DELIVER Trial that investigated the efficacy and safety of dapagliflozin according to frailty in patients with heart failure, then looks at a separate paper on the DELIVER Trial that examines dapagliflozin for heart failure according to body mass index. Finally, Dr. Bhatt examines a prospective cohort study of UK Biobank participants that looked at the association between device-measured physical activity and incident heart failure.

134 Listeners

321 Listeners

504 Listeners

167 Listeners

906 Listeners

298 Listeners

1,150 Listeners

65 Listeners

39 Listeners

194 Listeners

94 Listeners

367 Listeners

437 Listeners

375 Listeners

32 Listeners